e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Adverse events of antituberculosis treatment and comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Rapid oral desensitization to anti-tuberculosis drugs
H. Daghfous, H. Zaibi, S. Merai, O. Kahloul, F. Tritar (Ariana, Tunisia)
Source:
Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Session:
Adverse events of antituberculosis treatment and comorbidities
Session type:
Thematic Poster Session
Number:
3144
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Daghfous, H. Zaibi, S. Merai, O. Kahloul, F. Tritar (Ariana, Tunisia). Rapid oral desensitization to anti-tuberculosis drugs. Eur Respir J 2010; 36: Suppl. 54, 3144
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Evaluation of antituberculous drugs administration
Source: Eur Respir J 2002; 20: Suppl. 38, 547s
Year: 2002
Initial antituberculosis drugs resistance
Source: Eur Respir J 2006; 28: Suppl. 50, 12s
Year: 2006
Hepatotoxicity due to antituberculosis drug treatment
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II
Year: 2008
Desensitization therapy for allergic reactions of antituberculous drugs
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Manifestations of hypersensitivity to anti-tuberculosis drugs
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020
Year: 2020
Anti-tuberculosis drugs
Source: International Congress 2017 – State of the art session: "Respiratory infections"
Year: 2017
Paradoxical response to adequate antituberculosis treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 724s
Year: 2004
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Source: Eur Respir J , 49 (4) 1700173; DOI: 10.1183/13993003.00173-2017
Year: 2017
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Source: Eur Respir J , 49 (4) 1700317; DOI: 10.1183/13993003.00317-2017
Year: 2017
Availability of anti-tuberculosis drugs in Europe
Source: Eur Respir J 2012; 40: 500-503
Year: 2012
Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Rational use of tuberculosis drugs to prevent the development of drug resistance
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Novel drug regimens against MDR-TB
Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis
Year: 2016
Side-effect in the treatment of pulmonary tuberculosis by first-line drugs
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009
Cardiotoxicity of a complex of anti-tuberculosis drugs with the inclusion of fluoroquinolones and bedaquiline in an experiment on rats
Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept